KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Long-Term Investments (2018 - 2019)

Esperion Therapeutics' Long-Term Investments history spans 2 years, with the latest figure at $733000.0 for Q1 2019.

  • For Q1 2019, Long-Term Investments fell 98.27% year-over-year to $733000.0; the TTM value through Mar 2019 reached $733000.0, down 98.27%, while the annual FY2018 figure was $243000.0, N/A changed from the prior year.
  • Long-Term Investments reached $733000.0 in Q1 2019 per ESPR's latest filing, up from $243000.0 in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $42.4 million in Q1 2018 to a low of $243000.0 in Q4 2018.